Cell line · CVCL_3422
Papers75
1 to 20 of 75
Download this page as JSON| Paper | Journal | Year | How we know | Retracted | Source |
|---|---|---|---|---|---|
| Targeting bromodomain and extra-terminal proteins reprograms macrophages and inhibits breast cancer progression. | Front Immunol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| In vivo CRISPR screening identifies metastasis suppressors in triple-negative breast cancer. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| FET proteins and PARylation-dependent condensates promote replication fork reversal and genome stability. | Nat Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of cyclin-dependent kinases 12/13 using CT7439 as a treatment for colorectal cancer with CDK12 upregulation. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Loss of IGF-1R impairs DNA-PKcs recruitment to chromatin leading to defective end-joining. | Mol Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| An antibody-drug conjugate designed through clone and isotype selection restricts the growth of CSPG4-expressing triple-negative breast cancer. | NPJ Precis Oncol | 2026 | Its Methods give the RRID and name the line | PubMed | |
| 3D "Emboli" Culture Models Epithelial Breast Cancer Cell Oxidative Mitochondrial Metabolism with Relevance for Lung Metastasis. | Cancer Res Commun | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response Aberrations: Preclinical and Phase Ib Results. | Clin Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| Integrative CRISPR Screening and RNA Analyses Discover an Essential Role for PUF60 Interactions with 3' Splice Sites in Cancer Progression. | Cancer Res | 2026 | Its Methods give the RRID and name the line | PubMed | |
| The CIP2A-TOPBP1 axis facilitates mitotic DNA repair via MiDAS and MMEJ. | Nat Commun | 2025 | Its Methods give the RRID and name the line | PubMed | |
| MYC inhibition by Omomyc causes DNA damage and overcomes PARPi resistance in breast cancer. | Cell Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| High-throughput combination screening of Pidnarulex and other G-quadruplex ligands in multi-cell type tumor spheroids. | SLAS Discov | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PARP inhibitor and PRMT5 inhibitor synergy is independent of BRCA1/2 and MTAP status in breast cancer cells. | Sci Rep | 2025 | Its Methods give the RRID and name the line | PubMed | |
| PCBP2 Mediates Olaparib Resistance in Breast Cancer by Inhibiting m6A Methylation to Stabilize PARP1 mRNA. | Cancer Res | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Curcumin Induces Homologous Recombination Deficiency by BRCA2 Degradation in Breast Cancer and Normal Cells. | Cancers (Basel) | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Depleting the Action of EZH2 through PI3K-mTOR Inhibition to Overcome Metastasis and Immunotherapy Resistance in Triple-Negative Breast Cancer. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| E-Cadherin Is a Structuring Component of Invadopodia in Pancreatic Cancer. | J Cell Mol Med | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of MCL-1 and MEK Overcomes MEK Inhibitor Resistance in Triple-Negative and Inflammatory Breast Cancers. | Mol Cancer Ther | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Defining the regulatory logic of breast cancer using single-cell epigenetic and transcriptome profiling. | Cell Genom | 2025 | Its Methods give the RRID and name the line | PubMed | |
| Inhibition of proteolytic and ATPase activities of the proteasome by the BTK inhibitor CGI-1746. | iScience | 2024 | Its Methods give the RRID and name the line | PubMed |
cell-lines-2026-11-14-0.1.0
Sources 4
- CellosaurusCC BY 4.0, with credit to Cellosaurus (SIB)
- PubMed Central's articlesTitles shown only for CC0, CC BY and public domain articles
- NLM's PMC Article DatasetsCourtesy of NLM, which does not endorse this database
- PubMedNLM's terms
Each source's terms
- CellosaurusCC BY 4.0. Cellosaurus's README: "we have chosen to apply the Creative Commons Attribution 4.0 International (CC BY 4.0) license to Cellosaurus (https://creativecommons.org/licenses/by/4.0/). This means that you are free to copy and redistribute Cellosaurus in any medium or format. You can remix, transform, and build upon Cellosaurus for any purpose, even commercially. You must give appropriate credit, provide a link to the license, and indicate if changes were made." Copyright (c) CALIPHO group, SIB Swiss Institute of Bioinformatics. Read on 14 Nov 2026 at https://ftp.expasy.org/databases/cellosaurus/README
- PubMed Central's articlesEach article's own license. Its words show only under CC0, CC BY or public domain
- NLM's PMC Article DatasetsNLM's PMC Article Datasets on AWS, https://registry.opendata.aws/ncbi-pmc. Its terms: users "acknowledge NLM as the source of the data in a clear and conspicuous manner", do not use the PubMed Central wordmark or the PMC logo, do not "indicate or imply that NLM/NIH/HHS has endorsed" a product, and "only distribute data that are licensed for redistribution". Each article keeps its own license: https://pmc.ncbi.nlm.nih.gov/about/copyright/
- PubMedNLM's terms
Cellosaurus, SIB Swiss Institute of Bioinformatics, https://www.cellosaurus.org, CC BY 4.0. Its problem notes are given in its own words.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/cell-lines/v1/CVCL_3422/papers